The Gradually Expanding Scope for Biowaivers of Oral Products: An Overview
The regulatory paradigm is relaxing gradually without compromising the safety, efficacy and the quality of the drug product and, most importantly, a perceptible scientific consensus is maturing towards the need of affordable medicines. The establishment of bioequivalence (BE) is no longer being considered to be accomplished only by in vivo studies in oral drug products. The potential use of in vitro dissolution testing in lieu of BE studies has now been regulatory adopted and is commonly referred to as “biowaiver”. Further, the advent of biopharmaceutics classification system (BCS) and in vitro-in vivo correlation (IVIVC) proves to be sound milestones and signifies that we are incessantly forwarding towards a scenario that would reduce regulatory burden, save time and make the drug products more affordable while ensuring their quality. This review outlines, the current and pertinent regulatory environment for biowaiver based on in vitro drug dissolution, primarily as per the FDA perspective. The rationale used for qualification of biowaiver for different strengths, post-approval changes and multi-source products are discussed along with the role of BCS and IVIVC.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: November 1, 2016
More about this publication?
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites